Newsfeed

Bei diesem Bereich handelt es sich um eine mögliche Darstellungsform der Integration von Nachrichtenquellen mit Bezug zu börsennotierten Unternehmen.
Als Präsentationsebene fungiert ein Template, dass an Kurznachrichtenservices angelehnt ist, bei dem sich Nutzer einen schnellen Überblick über aktuelle Nachrichten verschaffen können. Die Detailansichten ermöglichen bei Interesse weitergehende Recherchen.

Dieser Newsfeed ist eine Zusammenstellung aktueller Nachrichten, die aus Direktanbindungen von TopTier NewsWire-Services mit Bezug zu börsennotierten Unternehmen stammen. Dieser Feed hier dient ausschließlich Demonstrationszwecken. Sektoren-spezifische Nachrichten, Public Relations sowie Produktinformationen können über die GICS Portale > Bereich Sektor-Intelligence abgerufen werden.

US01438T1060
Filter zurücksetzen
Do you already know our new terminal view? Click here.
FIGI: BBG0029H8ZF6
ALDX
Aldeyra Therapeutics Inc
GICS: Health Care · SECTOR: Healthcare · SUB-SECTOR: Biotechnology · THEMEFOLIO: $HLTH
NAME
Aldeyra Therapeutics Inc
ISIN
US01438T1060
TICKER
ALDX
MIC
XNAS
REUTERS
ALDX.OQ
BLOOMBERG
ALDX US
Do., 02.04.2026       Aldeyra Therapeutics
US01438T1060

New York, New York--(Newsfile Corp. - April 2, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of securities of Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) between November 3, 2023 and March 16, 2026, both dates inclusive (the "Class Period"). A class action lawsuit...
Zur Nachricht
Aldeyra Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 02.04.2026       Aldeyra Therapeutics
US01438T1060

NEW YORK, April 2, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Aldeyra Therapeutics, Inc. ("Aldeyra" or the "Company") (NASDAQ: ALDX).   Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-m...
Zur Nachricht
Aldeyra Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mi., 01.04.2026       Aldeyra Therapeutics
US01438T1060

New York, New York--(Newsfile Corp. - April 1, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of securities of Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) between November 3, 2023 and March 16, 2026, both dates inclusive (the "Class Period"). A class action la...
Zur Nachricht
Aldeyra Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mi., 01.04.2026       Aldeyra Therapeutics
US01438T1060

The DJS Law Group reminds investors of a class action lawsuit against Aldeyra Therapeutics, Inc. (“Aldeyra” or “the Company”) (NASDAQ: ALDX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Shareholders who purchased shares of ALDX during...
Zur Nachricht
Aldeyra Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mi., 01.04.2026       Aldeyra Therapeutics
US01438T1060

LOS ANGELES, April 1, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Aldeyra Therapeutics, Inc. ("Aldeyra" or "the Company") (NASDAQ: ALDX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shar...
Zur Nachricht
Aldeyra Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mi., 01.04.2026       Aldeyra Therapeutics
US01438T1060

The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed on behalf of investors who acquired Aldeyra Therapeutics (“Aldeyra” or the “Company”) (NASDAQ:ALDX) securities during the period of November 3, 2023 through March 16, 2026, inclusive (“the Class Period”). If you suffered a loss on your Aldeyra investments, y...
Zur Nachricht
Aldeyra Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mi., 01.04.2026       Aldeyra Therapeutics
US01438T1060

NEW YORK, March 31, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of securities of Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) between...
Zur Nachricht
Aldeyra Therapeutics
Charts & Research Termsheets Terminal
Permalink
Di., 31.03.2026       Aldeyra Therapeutics
US01438T1060

The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Aldeyra Therapeutics, Inc. (“Aldeyra” or “the Company”) (NASDAQ: ALDX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission...
Zur Nachricht
Aldeyra Therapeutics
Charts & Research Termsheets Terminal
Permalink
Di., 31.03.2026       Aldeyra Therapeutics
US01438T1060

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Aldeyra Therapeutics, Inc. (“Aldeyra” or the “Company”) (NASDAQ: ALDX) and reminds investors of the May 29, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. This...
Zur Nachricht
Aldeyra Therapeutics
Charts & Research Termsheets Terminal
Permalink
Di., 31.03.2026       Aldeyra Therapeutics
US01438T1060

Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) securities between November 3, 2023 and March 16, 2026. Defendant Aldeyra describes itself as a “biotechnology company devoted to discovering innovative therapies designed to treat i...
Zur Nachricht
Aldeyra Therapeutics
Charts & Research Termsheets Terminal
Permalink
Silent Ad
Di., 31.03.2026       Aldeyra Therapeutics
US01438T1060

Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of the securities of Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) between November 3, 2023 and March 16, 2026, both dates inclusive (the “Class Period”). The lawsuit seeks to recover damages for Aldeyra investors under the federal...
Zur Nachricht
Aldeyra Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mo., 30.03.2026       Aldeyra Therapeutics
US01438T1060

New York, New York--(Newsfile Corp. - March 30, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Aldeyra Therapeutics, Inc. ("Aldeyra Therapeutics, Inc.") (NASDAQ: ALDX) concerning potential violations of the federal securities laws.Throughout 2024 and 2025, Aldeyra's made forward-looking statements regard...
Zur Nachricht
Aldeyra Therapeutics
Charts & Research Termsheets Terminal
Permalink
So., 29.03.2026       Aldeyra Therapeutics
US01438T1060

New York, New York--(Newsfile Corp. - March 29, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) resulting from allegations that Aldeyra may have issued materially misleading business information to the inv...
Zur Nachricht
Aldeyra Therapeutics
Charts & Research Termsheets Terminal
Permalink
Fr., 27.03.2026       Aldeyra Therapeutics
US01438T1060

New York, New York--(Newsfile Corp. - March 27, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) resulting from allegations that Aldeyra may have issued materially misleading business information to the inv...
Zur Nachricht
Aldeyra Therapeutics
Charts & Research Termsheets Terminal
Permalink
Fr., 27.03.2026       Aldeyra Therapeutics
US01438T1060

New York, New York--(Newsfile Corp. - March 27, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Aldeyra Therapeutics, Inc. ("Aldeyra Therapeutics, Inc.") (NASDAQ: ALDX) concerning potential violations of the federal securities laws.Throughout 2024 and 2025, Aldeyra's made forward-looking statements regard...
Zur Nachricht
Aldeyra Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 26.03.2026       Aldeyra Therapeutics
US01438T1060

NEW YORK, March 26, 2026 /PRNewswire/ --  Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) resulti...
Zur Nachricht
Aldeyra Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 26.03.2026       Aldeyra Therapeutics
US01438T1060

NEW YORK, March 26, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Aldeyra Therapeutics, Inc. ("Aldeyra" or the "Company") (NASDAQ: ALDX).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.  ...
Zur Nachricht
Aldeyra Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mi., 25.03.2026       Aldeyra Therapeutics
US01438T1060

Aldeyra Therapeutics Stock Falls After FDA Issues Complete Response Letter Rejecting Reproxalap for Dry Eye DiseaseNEW YORK, March 25, 2026 /PRNewswire/ -- Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) shares dropped approximately 70% after the FDA issued a Complete Response Letter for reproxalap, the Company's dry-eye therapy candidate, citing insuff...
Zur Nachricht
Aldeyra Therapeutics
Charts & Research Termsheets Terminal
Permalink
Di., 24.03.2026       Aldeyra Therapeutics
US01438T1060

New York, New York--(Newsfile Corp. - March 24, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) resulting from allegations that Aldeyra may have issued materially misleading business information to the inv...
Zur Nachricht
Aldeyra Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mo., 23.03.2026       Aldeyra Therapeutics
US01438T1060

New York, New York--(Newsfile Corp. - March 23, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) resulting from allegations that Aldeyra may have issued materially misleading business information to the inv...
Zur Nachricht
Aldeyra Therapeutics
Charts & Research Termsheets Terminal
Permalink
Silent Ad
Sa., 21.03.2026       Aldeyra Therapeutics
US01438T1060

NEW YORK, March 21, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) resultin...
Zur Nachricht
Aldeyra Therapeutics
Charts & Research Termsheets Terminal
Permalink
Sa., 21.03.2026       Aldeyra Therapeutics
US01438T1060

Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) resulting from allegations that Aldeyra may have issued materially misleading business information to the investing public. So What: If you purchased Aldeyra secu...
Zur Nachricht
Aldeyra Therapeutics
Charts & Research Termsheets Terminal
Permalink
Fr., 20.03.2026       Aldeyra Therapeutics
US01438T1060

NEW YORK, March 19, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Aldeyra Therapeutics, Inc. ("Aldeyra" or the "Company") (NASDAQ: ALDX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980....
Zur Nachricht
Aldeyra Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mi., 18.03.2026       Aldeyra Therapeutics
US01438T1060

Aldeyra Therapeutics Touted Reproxalap's Regulatory Path While FDA Ultimately Found Insufficient EfficacyNEW YORK, March 18, 2026 /PRNewswire/ -- Investors in Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) lost approximately 70% of their holdings after the FDA issued a Complete Response Letter for reproxalap, citing insufficient efficacy for the treatm...
Zur Nachricht
Aldeyra Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mi., 18.03.2026       Aldeyra Therapeutics
US01438T1060

New York, New York--(Newsfile Corp. - March 18, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Aldeyra Therapeutics, Inc. ("Aldeyra Therapeutics, Inc.") (NASDAQ: ALDX) concerning potential violations of the federal securities laws.Throughout 2024 and 2025, Aldeyra's made forward-looking statements regard...
Zur Nachricht
Aldeyra Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mi., 18.03.2026       Aldeyra Therapeutics
US01438T1060

Boston, Massachusetts--(Newsfile Corp. - March 18, 2026) - Block & Leviton is investigating Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) for potential securities law violations. Investors who have lost money in their Aldeyra Therapeutics, Inc. investment should contact the firm to learn more about how they might recover those losses. For more deta...
Zur Nachricht
Aldeyra Therapeutics
Charts & Research Termsheets Terminal
Permalink
Di., 17.03.2026       Aldeyra Therapeutics
US01438T1060

San Diego, California--(Newsfile Corp. - March 17, 2026) - Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Aldeyra Therapeutics (NASDAQ: ALDX). The investigation focuses on Aldeyra Therapeutics executive officers and whether investor losses may be recovered under federal securities laws. What if I purchased Aldeyra...
Zur Nachricht
Aldeyra Therapeutics
Charts & Research Termsheets Terminal
Permalink
Di., 17.03.2026       Aldeyra Therapeutics
US01438T1060

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated diseases, today announced receipt of a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) for the New Drug Application (NDA) of reproxalap, an investi...
Zur Nachricht
Aldeyra Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mi., 18.02.2026       Aldeyra Therapeutics
US01438T1060

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated diseases, today announced that Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer, will participate virtually in a fireside chat at the Oppenheimer 36th Annual Heal...
Zur Nachricht
Aldeyra Therapeutics
Charts & Research Termsheets Terminal
Permalink
Di., 16.12.2025       Aldeyra Therapeutics
US01438T1060

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated diseases, today announced that the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) target action date for the reproxalap New Drug A...
Zur Nachricht
Aldeyra Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 13.11.2025       Aldeyra Therapeutics
US01438T1060

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated diseases, today announced at a research and development webcast the expansion of the RASP platform to include programs in central nervous system diseases associated with inflammat...
Zur Nachricht
Aldeyra Therapeutics
Charts & Research Termsheets Terminal
Permalink
Di., 11.11.2025       Aldeyra Therapeutics
US01438T1060

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated diseases, today announced that Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the 2025 Jefferies Global Healthcare Confe...
Zur Nachricht
Aldeyra Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 06.11.2025       Aldeyra Therapeutics
US01438T1060

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company developing innovative therapies for the treatment of immune-mediated diseases, today announced that the company will host a Research & Development Update webcast on Thursday, November 13, 2025 at 8:00 a.m. ET. Aldeyra will provide a review of pipeline...
Zur Nachricht
Aldeyra Therapeutics
Charts & Research Termsheets Terminal
Permalink
Di., 28.10.2025       Aldeyra Therapeutics
US01438T1060

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated diseases, today announced achievement of statistically significant improvement in liver function in patients treated with ADX-629, an investigational new drug candidate, and focus...
Zur Nachricht
Aldeyra Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mi., 03.09.2025       Aldeyra Therapeutics
US01438T1060

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today announced that Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright 27th Ann...
Zur Nachricht
Aldeyra Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 28.08.2025       Aldeyra Therapeutics
US01438T1060

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that the European Medicines Agency (EMA) has granted Orphan Designation for ADX-2191 (methotrexate intravitreal injection, USP) for the treatment of primary large B-Cell lymphomas of immune-privileged sites, including primary vitreoretinal lymphoma. There is currently no approved...
Zur Nachricht
Aldeyra Therapeutics
Charts & Research Termsheets Terminal
Permalink
Di., 19.08.2025       Aldeyra Therapeutics
US01438T1060

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that the U.S. Food and Drug Administration (FDA) has granted fast track designation for ADX-2191 (methotrexate intravitreal injection, USP) for the treatment of retinitis pigmentosa. There is currently no approved treatment for patients with most forms of retinitis pigmentosa, a c...
Zur Nachricht
Aldeyra Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 24.07.2025       Aldeyra Therapeutics
US01438T1060

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that the European Medicines Agency (EMA) has granted Orphan Designation for ADX-2191 (methotrexate intravitreal injection) for the treatment of inherited retinal dystrophies of the rod-dominant phenotype, including retinitis pigmentosa. There are currently no approved drug treatme...
Zur Nachricht
Aldeyra Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 17.07.2025       Aldeyra Therapeutics
US01438T1060

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the resubmitted New Drug Application (NDA) for topical ocular reproxalap, a first-in-class investigational new drug candidate, for the treatment of the signs and symptoms of dry eye disease. The FDA assigned...
Zur Nachricht
Aldeyra Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 26.06.2025       Aldeyra Therapeutics
US01438T1060

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced receipt of a Special Protocol Assessment Agreement Letter from the U.S. Food and Drug Administration (FDA) for ADX-2191 (methotrexate injection, USP), an investigational drug candidate, for the treatment of primary vitreoretinal lymphoma (PVRL), a rare and potentially fatal cancer...
Zur Nachricht
Aldeyra Therapeutics
Charts & Research Termsheets Terminal
Permalink
Di., 17.06.2025       Aldeyra Therapeutics
US01438T1060

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune‑mediated and metabolic diseases, today announced the resubmission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for topical ocular reproxalap, an investiga...
Zur Nachricht
Aldeyra Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 29.05.2025       Aldeyra Therapeutics
US01438T1060

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today announced that Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the 2025 Jefferies Global He...
Zur Nachricht
Aldeyra Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mo., 12.05.2025       Aldeyra Therapeutics
US01438T1060

NEW YORK, May 12, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  Aldeyra Therapeutics, Inc. ("Aldeyra" or the "Company") (NASDAQ: ALDX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980....
Zur Nachricht
Aldeyra Therapeutics
Charts & Research Termsheets Terminal
Permalink
Di., 06.05.2025       Aldeyra Therapeutics
US01438T1060

NEW YORK, May 6, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Aldeyra Therapeutics, Inc. ("Aldeyra" or the "Company") (NASDAQ: ALDX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980....
Zur Nachricht
Aldeyra Therapeutics
Charts & Research Termsheets Terminal
Permalink
Di., 06.05.2025       Aldeyra Therapeutics
US01438T1060

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today announced the achievement of the primary endpoint in a Phase 3 randomized, double-masked, vehicle-controlled dry eye chamber trial of 0.25% reproxala...
Zur Nachricht
Aldeyra Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mo., 05.05.2025       Aldeyra Therapeutics
US01438T1060

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced it will host a webcast and conference call on Tuesday, May 6, 2025, at 8:00 a.m. ET to announce topline results from Phase 3 dry eye disease clinical trials of reproxalap. The dial-in numbers are (833) 470-1428 for domestic callers and (404) 975-4839 for international callers. The...
Zur Nachricht
Aldeyra Therapeutics
Charts & Research Termsheets Terminal
Permalink
Di., 29.04.2025       Aldeyra Therapeutics
US01438T1060

LOS ANGELES, April 29, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Aldeyra Therapeutics, Inc. ("Aldeyra" or "the Company") (NASDAQ: ALDX) for violations of the securities laws....
Zur Nachricht
Aldeyra Therapeutics
Charts & Research Termsheets Terminal
Permalink
Fr., 25.04.2025       Aldeyra Therapeutics
US01438T1060

Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) resulting from allegations that Aldeyra may have issued materially misleading business information to the investing public. So What: If you purchased Aldeyra secur...
Zur Nachricht
Aldeyra Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 24.04.2025       Aldeyra Therapeutics
US01438T1060

LOS ANGELES, April 24, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Aldeyra Therapeutics, Inc. ("Aldeyra" or "the Company") (NASDAQ: ALDX) for violations of the securities laws....
Zur Nachricht
Aldeyra Therapeutics
Charts & Research Termsheets Terminal
Permalink
Di., 22.04.2025       Aldeyra Therapeutics
US01438T1060

NEW YORK, April 22, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Aldeyra Therapeutics, Inc. ("Aldeyra" or the "Company") (NASDAQ: ALDX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980....
Zur Nachricht
Aldeyra Therapeutics
Charts & Research Termsheets Terminal
Permalink